As discussed in greater detail herein, isolated epitope peptides derived from MPHOSPH1 bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above-mentioned MPHOSPH1-derived amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well as pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, and pharmaceutical agents or compositions of this invention find particular utility in either or both of the treatment and prevention of cancers and tumors, including, for example, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, gastric cancer, NSCLC, lymphoma, osteosarcoma, prostate cancer, renal cancer and soft tissue tumor.如於此所詳細討論,來自MPHOSPH1經分離的胜肽,其與一人類白血球組織抗原結合且誘發細胞毒殺性T淋巴球,且因此適合用於癌症免疫治療,特別是癌症疫苗的背景中。本發明胜肽包括上述MPHOSPH1衍生之胺基酸序列與其經修飾之變體,於經修飾之變體中,一、二或數個胺基酸被取代、刪除、插入或加入,提供維持原始序列必不可缺之細胞毒殺性T淋巴球誘發能力的該經修飾之胜肽。更提供編碼出任何上述胜肽的多核苷酸與包括任何上述胜肽或多核苷酸的藥學試劑或組合物。本發明之胜肽、多核苷酸及藥學試劑或組合物於癌症與腫瘤之治療與避免之任一或兩者中提供特別的效用,癌症與腫瘤包括,例如,膀胱癌、乳癌、子宮頸癌(cervical cancer)、膽管細胞癌(cholangiocellular carcinoma)、慢性骨髓性白血病(chronic myeloid leukemia,CML)、大腸癌(colorectal cancer)、胃癌、非小細胞肺癌(non-small cell lung cancer,NSCLC)、淋巴癌、骨肉瘤(osteosarcoma)、攝護腺癌(prostate cancer)、腎癌(renal cancer)與軟組織腫瘤
